38 matches for your search in the start-up spotlight
rss
NEOGAP Therapeutics AB is a privately held clinical stage biopharmaceutical company with the main focus on immuno-oncology. The company was founded in 2016 by Dr. Hans Grönlund. We are located at Cancer Center Karolinska at Karolinska University Hospital, Solna, Sweden. Our vision is to ...
Inimmue is a new biotechnology company founded by pharmaceutical industry veterans focused on developing next generation immunotherapeutics.
Exeliom Biosciences is a clinical-stage biopharmaceutical company specialized in the development of microbiome-based immunotherapies with a mission to bring innovation to the treatment of inflammatory bowel diseases, cancer, and infectious diseases. Its lead asset, EXL01, a rationally selected, ...
Astraveus is developing the next generation of cell and gene therapy (CGT) manufacturing solutions. Astraveus's cell foundries miniaturize and automate cell and gene therapy manufacturing in a unique, modular, end-to-end, microfluidic solution that mimics the elegance of natural systems. The deep ...
TransCode is an RNA oncology company created on the belief that cancer can be effectively treated using RNA therapeutics. The Company has created a platform of drug candidates designed to target a variety of tumor types with the objective of significantly improving patient outcomes. The Company’s ...
Kymera is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways inaccessible with conventional therapeutics. Kymera’s Pegasus platform is a powerful drug discovery engine, advancing novel small molecule ...
CimCure is a 2016 spin-off from Amsterdam UMC. CimCure focuses on the design and development of a novel class of active cancer immunotherapies. The company develops cancer vaccines through its proprietary Immune-Boost (iBoost) technology of targeted conjugate vaccines. They have identified ...
FundaMental Pharma GmbH is a neuroscience company with portfolio at the preclinical stage, which was spun out of the Department of Neurobiology at Heidelberg University, Germany. First-in class NMDAR/TRPM4 (N/T) Interface Inhibitors selectively abolish extrasynaptic NMDARs-induced glutamate ...
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop ...
Selmod is a Swiss biotech start-up and was founded in May 2016 in Basel, Switzerland. Selmod develops innovative antibiotics for the treatment of life-threatening, multi-drug resistant infections. The company’s focus is on discovery and early clinical development of small molecules and peptides ...
